-
公开(公告)号：US10800827B2
公开(公告)日：2020-10-13
申请号：US16199774
申请日：2018-11-26
Applicant: Merck Sharp & Dohme Corp.
Inventor： Songnian Lin , Lin Yan , Pei Huo , Dmitri Pissarnitski , Danqing Feng , Ravi Nargund , Yuping Zhu , Ahmet Kekec , Christina B. Madsen-Duggan , Zhi-Cai Shi , Zhicai Wu , Yingjun Mu
Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
-
公开(公告)号：US20160289207A1
公开(公告)日：2016-10-06
申请号：US15035255
申请日：2014-11-10
Applicant: MERCK SHARP & DOHME CORP.
Inventor： Duane DeMong , Michael Miller , Hong Liu , Xing Dai , Thomas Greshock , Andrew Stamford , Ravi Nargund
IPC: C07D401/04 , C07D401/14
CPC classification number: C07D401/04 , C07D231/56 , C07D401/14
Abstract: The present invention is directed to substituted indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Abstract translation: 本发明涉及取代的吲唑化合物，其是LRRK2激酶的有效抑制剂并且可用于治疗或预防涉及LRRK2激酶的疾病，例如帕金森病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及LRRK-2激酶的疾病中的用途。
-
3.发明申请TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C 有权四环杂环化合物及其用于治疗乙型肝炎的方法公开(公告)号：US20150368246A1
公开(公告)日：2015-12-24
申请号：US14766487
申请日：2014-02-03
Applicant: MERCK SHARP & DOHME CORP.
Inventor： Xing Dai , Hong Liu , Anandan Palani , Shuwen He , Zhong Lai , Ravi Nargund , Karen Marcantonio , Dong Xiao , Linda L. Brockunier , Nicolas Zorn , Qun Dang , Xuanjia Peng , Peng Li
IPC: C07D471/14 , C07D519/00 , C07D471/04 , A61K45/06 , A61K31/675 , C07D471/20 , A61K31/5377 , A61K31/519 , C07F9/6512
CPC classification number: C07D471/14 , A61K31/519 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D471/04 , C07D471/20 , C07D487/14 , C07D519/00 , C07F9/65128 , A61K2300/00
Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. I
Abstract translation: 本发明涉及可用作丙型肝炎病毒（HCV）NS5B聚合酶抑制剂，这种化合物的合成以及这些化合物用于抑制HCV NS5B聚合酶活性用于治疗或预防HCV感染的用途的式I化合物和 抑制基于细胞的系统中的HCV病毒复制和/或病毒生产。 一世
-
4.发明申请TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 有权四环杂环化合物及其用于治疗病毒性疾病的方法公开(公告)号：US20140213571A1
公开(公告)日：2014-07-31
申请号：US14343450
申请日：2012-08-20
Applicant: MERCK SHARP & DOHME CORP.
Inventor： Nigel J. Liverton , Casey Cameron McComas , Joerg Habermann , Uwe Koch , Frank Narjes , Peng Li , Xuanjia Peng , Richard Soll , Hao Wu , Anandan Palani , Shuwen He , Xing Dai , Hong Liu , Zhong Lai , Clare London , Dong Xiao , Nicolas Zorn , Ravi Nargund
IPC: A61K31/553 , A61K31/519 , A61K31/437 , A61K31/407 , C07D498/22 , C07D498/14 , C07D491/147 , C07D491/052 , A61K45/06 , A61K31/5365 , C07D498/04
CPC classification number: A61K31/553 , A61K31/407 , A61K31/437 , A61K31/519 , A61K31/5365 , A61K45/06 , C07D491/052 , C07D491/147 , C07D498/04 , C07D498/14 , C07D498/22 , Y02A50/387 , Y02A50/389 , Y02A50/395 , A61K2300/00
Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
Abstract translation: 本发明涉及可用作丙型肝炎病毒（HCV）NS5B聚合酶抑制剂，这种化合物的合成以及这些化合物用于抑制HCV NS5B聚合酶活性用于治疗或预防HCV感染的式（I）化合物 并用于在基于细胞的系统中抑制HCV病毒复制和/或病毒生产。
-
公开(公告)号：US11058775B2
公开(公告)日：2021-07-13
申请号：US16092155
申请日：2017-04-21
Applicant: Merck Sharp & Dohme Corp.
Inventor： Anandan Palani , Zhiqiang Yang , Lin Yan , Songnian Lin , Pei Huo , Ravi Nargund
Abstract: Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.
-
Patent Agency Ranking
公开(公告)号：US11034661B2
公开(公告)日：2021-06-15
申请号：US16495883
申请日：2018-03-23
Applicant: Merck Sharp & Dohme Corp. , Liangqin Guo , Yongxin Han , Kun Liu , Shuwen He , Joseph Kozlowski , Ravi Nargund , Wensheng Yu , Hongjun Zhang , Qinglin Pu , Derun Li , Abdelghani Achab , Guoqing Li
Inventor： Liangqin Guo , Yongxin Han , Kun Liu , Shuwen He , Joseph Kozlowski , Ravi Nargund , Wensheng Yu , Hongjun Zhang , Qinglin Pu , Derun Li , Abdelghani Achab , Guoqing Li
IPC: C07D271/08 , C07D413/12
Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
-
公开(公告)号：US10689430B2
公开(公告)日：2020-06-23
申请号：US16301010
申请日：2017-05-23
Applicant: Merck Sharp & Dohme Corp.
Inventor： Songnian Lin , Lin Yan , Pei Huo , Dmitri Pissarnitski , Danqing Feng , Ravi Nargund , Christina Madsen-Duggan , Yuping Zhu , Ahmet Kekec , Zhicai Wu
Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
-
公开(公告)号：US20190338008A1
公开(公告)日：2019-11-07
申请号：US15759911
申请日：2016-10-21
Applicant: Anandan PALANI , Ravi NARGUND , Paul E. CARRINGTON , Tomi SAWYER , Qiaolin DENG , Antonello PESSI , Elisabetta BIANCHI , Fe-derica ORYIETO , Merck Sharp & Dohme Corp.
Inventor： Anandan Palani , Ravi Nargund , Paul E. Carrington , Tomi Sawyer , Qiaolin Deng , Antonello Pessi , Elisabetta Bianchi , Federica Orvieto
IPC: C07K14/605 , A61P3/04 , A61K38/28
Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
-
9.发明申请TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C 有权四环杂环化合物及其用于治疗乙型肝炎的方法公开(公告)号：US20150361101A1
公开(公告)日：2015-12-17
申请号：US14766462
申请日：2014-02-03
Applicant: Xing DAI , Anandan PALANI , Shuwen HE , Linda L. BROCKUNIER , Ravi NARGUND , Karen MARCANTONO , Nicolas Zorn , Dong XIAO , Xuanjia PENG , Tao GUO , MERCK SHARP & DOHME CORP.
Inventor： Xing Dai , Hong Liu , Anandan Palani , Shuwen He , Linda L. Brockunier , Ravi Nargund , Karen Marcantonio , Nicolas Zorn , Dong Xiao , Xuanjia Peng , Peng Li , Tao Guo
IPC: C07D519/00 , C07D471/14 , A61K31/4375 , A61K31/5025 , A61K31/438 , A61K31/55 , C07D471/22 , C07D471/04 , C07D471/20 , A61K45/06 , A61K31/519
CPC classification number: C07D519/00 , A61K31/4375 , A61K31/438 , A61K31/444 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61K31/55 , A61K45/06 , C07D471/04 , C07D471/14 , C07D471/20 , C07D471/22 , C07D487/14 , A61K2300/00
Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
Abstract translation: 本发明涉及可用作丙型肝炎病毒（HCV）NS5B聚合酶抑制剂，这种化合物的合成以及这些化合物用于抑制HCV NS5B聚合酶活性用于治疗或预防HCV感染的用途的式I化合物和 抑制基于细胞的系统中的HCV病毒复制和/或病毒生产。
-
公开(公告)号：US10793615B2
公开(公告)日：2020-10-06
申请号：US15759911
申请日：2016-10-21
Applicant: Merck Sharp & Dohme Corp. , Anandan Palani , Ravi Nargund , Paul E. Carrington , Tomi Sawyer , Qiaolin Deng , Antonello Pessi , Elisabetta Bianchi , Federica Orvieto
Inventor： Anandan Palani , Ravi Nargund , Paul E. Carrington , Tomi Sawyer , Qiaolin Deng , Antonello Pessi , Elisabetta Bianchi , Federica Orvieto
IPC: A61K38/00 , A61K38/28 , A61P3/04 , A61P7/12 , A61P3/10 , C07K14/435 , C07K14/605
Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.019 seconds)
